BIP_13-089

Measurement of Relaxin in the Serum and Cerebrospinal Fluid of Subjects With and Without the Relapsing Form of Multiple Sclerosis

This study will evaluate relaxin (RLX) levels in patients with multiple sclerosis.

Key Eligibilities:
-Females 18 to 45 years of age.
-Patients with suspected MS undergoing a lumbar puncture for diagnosis who have not received any immunomodulating or immunosuppressant medication, or
-Patients with stable MS willing to participate in the study, or
-Patients without evidence of inflammatory systemic or inflammatory central nervous system disease, who require CSF removal for some other cause.

**Other protocol-defined inclusion/exclusion criteria may apply. Please click on the NCT Number (below) to learn more about the study at clinicaltrials.gov.**
N/A
NCT01909492
Neurosciences
Multiple Sclerosis
Stanley Cohan, M.D., Ph.D.
Providence Health & Services
Hannah Voss
  • Providence St. Vincent Medical Center